The Rosen Law Firm, P.A. announces that it is investigating potential securities fraud claims against INSYS Therapeutics, Inc. (Nasdaq: INSY) resulting from allegations that the Company may have issued materially misleading business information to the investing public.
On December 12, 2013, the Company disclosed that it has received a subpoena from the Office of Inspector General of the Department of Health and Human Services (HHS) regarding an investigation of potential violations involving HHS programs. The subpoena concerns Subsys®, including INSYS' sales and marketing practices relating to this product. On this news, shares of INSYS fell $7.56 per share, or by approximately 17%, during intraday trading on December 13, 2013.
The Rosen Law Firm is preparing a class action lawsuit as a result of this adverse information. If you purchased INSYS securities, you may visit the website at http://rosenlegal.com to join the action. You may also contact Phillip Kim, Esq. or Jonathan Horne, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.Attorney Advertising. Prior results do not guarantee a similar outcome.